Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00369226
Status:
COMPLETED
Last Update Posted:
2013-07-25
First Post:
2006-08-24
Brief Title:
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
06-065
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
John Koreth MD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Millennium Pharmaceuticals Inc | INDUSTRY |
| Brigham and Womens Hospital | OTHER |